Digest Network Come funziona
Network
/
Società
Hu
Non verificato

Huonslab Co., Ltd.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

5 comunicati stampa

Guarda tutti i comunicati
22/12/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Huonslab Announces Submission of Biologics License Application for Recombinant Human Hyaluronidase ‘HYDIZYME™’
Fonte
Huonslab Co., Ltd.
Emittente
Business Wire
1.00
0
23/07/2025
Scienza
Medicina - Varie
Associazioni/Professionisti
Biotecnologia
Salute
Farmaceutica
Industria
Huonslab Secures Formulation Patent for Recombinant Human Hyaluronidase Product, HYDIZYME™
Fonte
Huonslab Co., Ltd.
Emittente
Business Wire
1.00
0
26/05/2025
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Industria
Huonslab Achieves Last-Patient-In (LPI) in Phase 1 Pivotal Study for Recombinant Human Natural Hyaluronidase PH20
Fonte
Huonslab Co., Ltd.
Emittente
Business Wire
1.00
0
02/04/2025
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Huonslab Announces Significantly Enhanced Bioavailability of SC Infliximab Co-formulated with HyDIFFUZE™ in Sprague-Dawley Rats; Abstract Selected for Presentation at AACR 2025
Fonte
Huonslab Co., Ltd.
Emittente
Business Wire
1.00
0
12/08/2024
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Industria
Huonslab Announces Issuance of Process Patent for HyDIFFUZETM Drug Delivery Platform and MFDS IND Clearance for HLB3-002
Fonte
Huonslab Co., Ltd.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0